Paracetamol Is Safe During Pregnancy, Says EU Medicines Regulator: Global Health Authorities Reaffirm Guidelines After Autistic Risk Rumors

Spread the Message

Read Time:4 Minute, 23 Second

Pregnant women and healthcare professionals received clear guidance this week as leading health agencies in Europe, the UK, and around the world reaffirmed that paracetamol (acetaminophen) remains the recommended pain relief option during pregnancy—a stance underscored by the European Medicines Agency (EMA) and supported by new statements following recent controversies in the United States.

On September 23, 2025, major health authorities including the EMA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) publicly restated their recommendations for paracetamol use in pregnancy. These statements came following remarks from U.S. President Donald Trump, who linked Tylenol (paracetamol’s U.S. brand name) and childhood autism—claims not supported by existing scientific evidence. The EMA announcement, echoed globally, aims to reassure expectant mothers and practitioners and provides clarity amid confusion and alarm triggered by recent U.S. policy announcements and media coverage.

Key Findings and Developments

The EMA confirms “no new evidence would require changes” to existing EU recommendations for paracetamol use during pregnancy.
Large-scale data from pregnant women indicate no risk of malformations in the developing fetus or newborn when paracetamol is used as directed.
Rigorous reviews, including those published by JAMA and the European Network of Teratology Information Services (ENTIS), have found study results inconclusive regarding neurodevelopmental disorders such as autism or ADHD, with no established link to paracetamol exposure.
The World Health Organization (WHO) notes that evidence for a link with autism “remains inconsistent”.

Expert Commentary

Dr. Alison Cave, Chief Safety Officer, UK MHRA:
“There is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol remains the recommended pain relief option for pregnant women when used as directed. Untreated pain and fever can pose risks to the unborn baby, so it is important to manage these symptoms with the recommended treatment”.

Alison Eddy, CEO, New Zealand College of Midwives:
“Paracetamol is widely considered the first-line, safest option for pregnant women who require pain relief or fever management. Used at the lowest effective dose for the shortest necessary time, there is no evidence of risk to babies”.

ENTIS Position Statement (2021):
“No association has been established between maternal acetaminophen use during pregnancy and neurodevelopmental disorders in children, including autism spectrum disorder”.

Context and Background

Paracetamol is the most commonly used pain and fever medication during pregnancy worldwide. In countries such as the UK, Australia, and Ireland, it is considered a Pregnancy Category A medication, meaning adequately controlled studies have shown no increased risk of harm to unborn children when used at recommended dosages.

Past concerns about paracetamol and neurodevelopmental risks trace back to a handful of observational studies. However, leading regulatory agencies—including EMA, MHRA, the Health Products Regulatory Authority (Ireland), and Medsafe (New Zealand)—regularly review safety data and have found no need to revise guidance. Guidelines continue to advise using the lowest effective dose for the shortest possible duration.

Implications for Public Health

Expectant mothers can continue to rely on paracetamol as the first-choice painkiller during pregnancy, provided they use it at the lowest effective dose for the shortest time necessary.

Untreated pain and fever themselves may pose risks to fetal development, underscoring why effective symptom management remains important.
Persistent caution and consulting a healthcare provider are still advised before taking any medication during pregnancy.
Calls for labeling changes in the U.S.—currently proposed by the FDA—do not reflect the consensus position of global health bodies.

Limitations and Counterarguments

Recent recommendations are based on a combination of observational studies and product safety surveillance. Observational research may be subject to confounding factors, and definitive randomized controlled trial evidence is unlikely due to ethical constraints.
Critics point to emerging research suggesting potential neurodevelopmental risks, yet these findings remain unproven and inconsistent; reviews by ENTIS and JAMA corroborate the EMA’s stance.
As always, guidelines may evolve as new high-quality research is published. Continuous monitoring by regulators ensures that recommendations reflect current best evidence.

What This Means for Daily Health Decisions

For minor aches, pains, or fevers during pregnancy, paracetamol can be considered the safest available option—avoid higher dosages and extended use without medical supervision.
Alternative pain relief options should be considered only in consultation with a healthcare provider, as some medicines (e.g., NSAIDs) are contraindicated in pregnancy.
If symptoms are severe or persistent, expectant mothers should always seek advice from their physician or midwife.

Diverse Perspectives

While European, UK, Australian, and New Zealand health regulators uniformly endorse paracetamol’s safety profile, the FDA’s intention to add a warning label has sparked a global debate about precaution versus current evidence.
Patient advocacy groups urge that communications remain evidence-based, transparent, and supportive without causing undue anxiety or restricting effective symptom management.

Medical Disclaimer

“Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.”